Targeted delivery of murine IFN-γ using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity

Journal of Interferon and Cytokine Research

Volumn 28, Issue 2, 2008, Pages 73-87

  Zeytin, Hasan ^a   Reali, Eva ^a,b   Zaharoff, David A ^a   Rogers, Connie J ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INGM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOWLPOX VIRUS; GENE EXPRESSION; IMMUNITY; INFECTION; LYMPH NODE; MICROENVIRONMENT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; VIRUS REPLICATION; WILD TYPE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; DNA, RECOMBINANT; FEMALE; FOWLPOX VIRUS; GENETIC VECTORS; IMMUNOLOGIC FACTORS; INJECTIONS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPH NODES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

AVES; FOWLPOX VIRUS; MURINAE; MUS;

EID: 39449139909     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0063     Document Type: Article

References (48)

1. + T cells. Nat Immunol 3:549-557.
2. Andoniou CE, van Dommelen SLH, Voigt V, Andrews DM, Brizard G, Asselin-Paturel C, Delale T, Stacey KJ, Trinchieri G, Degli-Esposito M. 2005. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective immunity. Nat Immunol 6:1011-1019.
3. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155-162.
4. Biron CA. 1997. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 9:24-34.
5. Borg C, Jalil A, Laderach D, Laderach D, Maruyama K, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, Zitvogel L. 2004. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization. Blood 104:3267-3275.
6. Buentke EL, Heffler C, Wilson JL, Wallin RP, Lofman C, Chambers BJ, Ljunggren HG, Scheynius A. 2002. Natural killer and dendritic cell contact in lesional atopic dermatitis skin-Malassezia-influenced cell interactions. J Invest Dermatol 119:850-857
7. Cerwenka A, Lanier LL. 2001. Natural killer cells, viruses and cancer. Nat Rev Immunol 1:41-49.
8. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. 2004. NK cell and DC interactions. Trends Immunol 25:47-52.
9. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. 2002. Targeted delivery of IFN-γ to tumor vessels uncouples antitumor from counteregulatory mechanisms. Cancer Res 65:2906-2913.
10. Dickerson EB, Akhtar N, Steinberg H, Wang Z-Y, Lindstrom MJ, Padilla ML, Auerbach R, Helfand SC. 2004. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2:663-673.
11. Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK, Herberman RB. 1985. A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother 20:193-197.
12. Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, Nemunaitis J, Honn DS. 2000. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther 7:1220-1230.
13. Gattacceca F, Pilatte T, Billard C, Monnet I, Moritz S, Le Carrou J, Eloit M, Jaurand M-C. 2002. Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 10:3298-3304.
14. George TC, Mason LH, Ortaldo JR, Kumar V, Bennett M. 1999. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J Immunol 162:2035-2043.
15. Hayakawa Y, Kelley JM, Westwood JA, Darcy PK, Diefenbach A, Rauler D, Smyth MJ. 2002. Tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169:5377-5381.
16. Jenkins S, Gritz L, Fedor C, O'Neill EM, Cohen LK, Panicali DL. 1991. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retrovir 7:991-998.
17. Jourdier T-M, Moste C, Bonnet M-C, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P. 2003. Local immunotherapy of spontaneous feline fibrosarcoma using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10:2126-2132.
18. Kaido T, Bandu MT, Maury C, Ferrantini M, Belardelli F, Gresser I. 1995. IFN-alpha1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int J Cancer 60:221-229.
19. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. 2005. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535-539.
20. Kantor J, Tran R, Greiner JW, Pestka S, Shively J, Schlom J. 1989. Modulation of carcinoembryonic antigen mRNA levels in human colon carcinoma cells by recombinant γ interferon. Cancer Res 49:2651-2655.
21. Karlhofer FM, Yokoyama WM. 1991. Stimulation of murine natural killer (NK) cells by a monoclonal antibody for the NK1.1 antigen. J Immunol 146:3662-3673.
22. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. 2001. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61:206-214.
23. Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, Rosell K, Whiteside T, Phillippe S, Acres B, Slos P, Squiban P, Ross M, Kendra K. 2003. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10:251-259.
24. Lee S-H, Zafer A, de Repentigny Y, Lothay R, Trembley ML, Gros P, Duplay P, Webb JR, Vidal SM. 2003. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J Exp Med 197:515-526.
25. Legrand FA, Verardi PH, Chan KS, Peng Y, Jones LA, Yilma TD. 2005. Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci USA 102:2940-2945.
26. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. 1994. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 68:8125-8130.
27. Mailliard RB, Son Y-I, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. 2001. Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol 171:2366-2373.
28. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Ysang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. 2005. Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720-731.
29. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. 2004. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat Immunol 5:1260-1265.
30. Mason LH, Gosselin P, Anderson SK, Fosler WE, Ortaldo JR, McVicar DW. 1997. Differential tyrosine phosphorylation of inhibitory versus activating Ly49 receptors and their recruitment of SHP-1 phosphatase. J Immunol 159:4187-4196.
31. Moretta L, Ferlazzo G, Mingari MC, Melioli G, Moretta A. 2003. Human natural killer cell function and their interactions with dendritic cells. Vaccine 21:S2/38-42.
32. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. 2002. Peptide-specific CD8 T regulatory cells use IFN-γ to elaborate TGF-β-based suppression. J Immunol 174:7625-7632.
33. Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W, Favrot M. 1998. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther 9:2481-2491.
34. Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU. 1987. Phase II studies of recombinant interferon g in metastatic renal cell carcinoma. J Biol Response Mod 6:20-27.
35. Rautenschlein S, Sharma JM, Winslow BJ, McMillen J, Junker D, Cochran M. 2000. Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 18:426-433.
36. Reali E, Canter D, Zeytin H, Schlom J, Greiner JW. 2005. Comparative studies of avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23:2909-2921.
37. Robbins PF, Kantor J, Salgaller M, Horan Hand P, Fernstein PD, Schlom J. 1991. Transduction and expression of the human carcinoembryonic antigen (CEA) gene in a murine colon carcinoma cell line. Cancer Res 51:3757-3762.
38. Sarkar S, Flores I, De Rosa C, Ozzello L, Ron Y, Pertka S. 1995. Injection of irradiated B16 melanoma genetically modified to secrete IFN-a causes regression of an established tumor. Int J Oncol 7:17-24.
39. + T cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 62:5058-5064.
40. Semino C, Angelini G, Poggi A, Rubartelli A. 2005. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factors HMGB1. Blood 106:609-616.
41. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. 2005. NKG2D function protects the host from tumor formation. J Exp Med 202:583-588.
42. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. 1998. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:1593-1598.
43. Stewart TJ, Smyth MJ, Fernando GJP, Frazer IH, Leggatt GR. 2003. Inhibition of early tumor growth requires Ja18-positive (natural killer T) cells. Cancer Res 63:3058-3060.
44. Suttles J, Schwarting GA, Stout RD. 1986. Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J Immunol 136:1586-1591.
45. Trinchieri G. 1989. Biology of natural killer cells. Adv Immunol 47:187-201.
46. 2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-γ synthesis. Immunology 111:298-305.
47. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. 2005. Natural-killer cells and dendritic cells: "l'union fait la force." Blood 106:2252-2258.
48. Weber JS, Rosenberg SA. 1990. Effects of murine class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst 82:755-761.